Cargando…
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
BACKGROUND: The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. METHODS: Relapsed...
Autores principales: | Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Hong, Jung Yong, Lee, Ho Sup, Oh, Sung Yong, Shin, Ho-Jin, Kong, Jee Hyun, Yi, Jun Ho, Sakamoto, Kana, Ko, Young Hyeh, Huh, Jooryung, Lee, Seung-Sook, Takeuchi, Kengo, Shin, Dong-Yeop, Suh, Cheolwon, Kim, Won Seog |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842512/ https://www.ncbi.nlm.nih.gov/pubmed/31707975 http://dx.doi.org/10.1186/s12885-019-6303-z |
Ejemplares similares
-
Primary mediastinal large B-cell lymphoma: a single-center experience in Korea
por: Ahn, Heui June, et al.
Publicado: (2014) -
GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017) -
Clinicopathologic Characteristics of T-cell Non-Hodgkin's Lymphoma: A Single Institution Experience
por: Ko, Ock Bae, et al.
Publicado: (2009) -
JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma
por: Kim, Min-Sun, et al.
Publicado: (2020) -
Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)